Fluvoxamine for the treatment of COVID-19.
作者信息
Marzolini Catia, Marra Fiona, Boyle Alison, Khoo Saye, Back David J
机构信息
Division of Infectious Diseases & Hospital Epidemiology, University Hospital Basel and University of Basel, Basel, Switzerland.
Department of Molecular and Clinical Pharmacology, Institute of Translational Medicine, University of Liverpool, Liverpool, UK; Department of Pharmacy, NHS Greater Glasgow and Clyde, Glasgow, UK.
出版信息
Lancet Glob Health. 2022 Mar;10(3):e331. doi: 10.1016/S2214-109X(21)00592-1.
Abstract
摘要
相似文献
1
Fluvoxamine for the treatment of COVID-19.
Lancet Glob Health. 2022 Mar;10(3):e331. doi: 10.1016/S2214-109X(21)00592-1.
2
Fluvoxamine for COVID-19?
Med Lett Drugs Ther. 2021 May 3;63(1623):69-70.
3
Fluvoxamine for the treatment of COVID-19.
Lancet Glob Health. 2022 Mar;10(3):e332. doi: 10.1016/S2214-109X(22)00006-7.
4
Fluvoxamine for the treatment of COVID-19.
Lancet Glob Health. 2022 Mar;10(3):e330. doi: 10.1016/S2214-109X(22)00003-1.
5
Fluvoxamine for the treatment of COVID-19.
Lancet Glob Health. 2022 Mar;10(3):e329. doi: 10.1016/S2214-109X(21)00590-8.
6
Fluvoxamine and COVID-19.
WMJ. 2022;121:P2.
7
Fluvoxamine for the Early Treatment of SARS-CoV-2 Infection: A Review of Current Evidence.
Drugs. 2021 Dec;81(18):2081-2089. doi: 10.1007/s40265-021-01636-5. Epub 2021 Dec 1.
8
Fluvoxamine for the treatment of COVID-19 - Author's reply.
Lancet Glob Health. 2022 Mar;10(3):e333. doi: 10.1016/S2214-109X(21)00588-X.
9
Heme oxygenase agonists-fluvoxamine, melatonin-are efficacious therapy for Covid-19.
Cell Stress Chaperones. 2022 Jan;27(1):3-4. doi: 10.1007/s12192-021-01246-w. Epub 2021 Nov 30.
10
Fluvoxamine for outpatients with COVID-19: where do we stand?
Lancet Glob Health. 2022 Jan;10(1):e2-e3. doi: 10.1016/S2214-109X(21)00501-5. Epub 2021 Oct 28.
引用本文的文献
1
Early Fluvoxamine Reduces the Risk for Clinical Deterioration in Symptomatic Outpatients with COVID-19: A Real-World, Retrospective, before-after Analysis.
Microorganisms. 2023 Aug 12;11(8):2073. doi: 10.3390/microorganisms11082073.
2
Prediction of CYP-Mediated Drug Interaction Using Physiologically Based Pharmacokinetic Modeling: A Case Study of Salbutamol and Fluvoxamine.
Pharmaceutics. 2023 May 24;15(6):1586. doi: 10.3390/pharmaceutics15061586.
3
Role of Cytochrome P450 2C9 in COVID-19 Treatment: Current Status and Future Directions.
Eur J Drug Metab Pharmacokinet. 2023 May;48(3):221-240. doi: 10.1007/s13318-023-00826-8. Epub 2023 Apr 24.
4
Trial Sequential Analysis and Updated Meta-Analysis of Fluvoxamine on Clinical Deterioration in Adult Patients with Symptomatic COVID-19 Infection.
Int J Environ Res Public Health. 2023 Feb 24;20(5):4088. doi: 10.3390/ijerph20054088.
5
Efficacy and safety of selective serotonin reuptake inhibitors in COVID-19 management: a systematic review and meta-analysis.
Clin Microbiol Infect. 2023 May;29(5):578-586. doi: 10.1016/j.cmi.2023.01.010. Epub 2023 Jan 16.
6
Selective serotonin reuptake inhibitors: New hope in the fight against COVID-19.
Front Pharmacol. 2022 Nov 30;13:1036093. doi: 10.3389/fphar.2022.1036093. eCollection 2022.
7
COVID-19 Treatment-Current Status, Advances, and Gap.
Pathogens. 2022 Oct 18;11(10):1201. doi: 10.3390/pathogens11101201.
8
Another Outcome of the COVID-19 Pandemic: The Possible Repurposing of Selective Serotonin Reuptake Inhibitors.
Clin Nurse Spec. 2022;36(5):241-243. doi: 10.1097/NUR.0000000000000696.
本文引用的文献
1
Effect of early treatment with fluvoxamine on risk of emergency care and hospitalisation among patients with COVID-19: the TOGETHER randomised, platform clinical trial.
Lancet Glob Health. 2022 Jan;10(1):e42-e51. doi: 10.1016/S2214-109X(21)00448-4. Epub 2021 Oct 28.
2
Overview of the pharmacokinetics of fluvoxamine.
Clin Pharmacokinet. 1995;29 Suppl 1:1-9. doi: 10.2165/00003088-199500291-00003.
Zotero 插件